Document is current
Any future updates will be listed below
-
Authors
Kuriyama, Kodai https://orcid.org/0000-0002-0829-6462
Watanabe, Mizuki
Okatani, Takeshi
Ota, Shuichi https://orcid.org/0000-0002-3631-244X
Takahashi, Hiroyuki
Kubo, Kohmei
Nakazawa, Hideyuki
Ozeki, Kazutaka
Kanda, Junya https://orcid.org/0000-0002-6704-3633
Kitano, Toshiyuki
Hiramoto, Nobuhiro
Uehara, Yasufumi
Miyazaki, Yasuhiko
Kanda, Yoshinobu https://orcid.org/0000-0002-4866-9307
Ichinohe, Tatsuo https://orcid.org/0000-0002-0393-4066
Atsuta, Yoshiko https://orcid.org/0000-0003-4404-2870
Kondo, Eisei
- License Information
-
More Information
Article History
Received: 17 June 2025
Revised: 17 September 2025
Accepted: 7 November 2025
First Online: 15 November 2025
Competing interests
: HT received honoraria from AstraZeneca plc, Bristol Myers Squibb, Chugai Pharma, Janssen, Kyowa Kirin, Meiji Seika Pharma, Nippon Shinyaku, Mundipharma, Ono Pharmaceutical, SymBio pharmaceuticals, Takeda Pharmaceutical, Eisai, Fujimoto and Sanofi. KO has received speaker honoraria from Janssen. The remaining authors declare no competing financial interests associated with this study.
: All methods were performed in accordance with the Declaration of Helsinki and relevant guidelines and regulations. This study was approved by the Institutional Review Board of the Japanese Red Cross Kyoto Daiichi Hospital (approval number: 1084). All participating patients provided written informed consent to the Japanese Society for Transplantation and Cellular Therapy at the time of registration.
